{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:52Z","timestamp":1764510532708,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja (RS)","doi-asserted-by":"publisher","award":["Grant No. III41004"],"award-info":[{"award-number":["Grant No. III41004"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s12253-015-0032-7","type":"journal-article","created":{"date-parts":[[2016,1,10]],"date-time":"2016-01-10T22:15:39Z","timestamp":1452464139000},"page":"567-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas"],"prefix":"10.1007","volume":"22","author":[{"given":"Jelena","family":"Jelicic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena Todorovic","family":"Balint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja Perunicic","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Novica","family":"Boricic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Micev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Stojsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darko","family":"Antic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosko","family":"Andjelic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Bila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Balint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biljana","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"key":"32_CR1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 9:717\u2013720","journal-title":"Ann Oncol"},{"key":"32_CR2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019\u20135032","journal-title":"Blood"},{"key":"32_CR3","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937\u20131947","journal-title":"N Engl J Med"},{"key":"32_CR4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159\u20132169","journal-title":"N Engl J Med"},{"key":"32_CR5","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313\u20132323","journal-title":"N Engl J Med"},{"key":"32_CR6","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/annonc\/mdp531","volume":"21","author":"A Bari","year":"2009","unstructured":"Bari A, Marcheselli L, Sacchi S et al (2009) Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 21:1486\u20131491","journal-title":"Ann Oncol"},{"key":"32_CR7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2008.07028.x","volume":"141","author":"MC Cox","year":"2008","unstructured":"Cox MC, Nofroni I, Laverde G et al (2008) Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 141:265\u2013268","journal-title":"Br J Haematol"},{"key":"32_CR8","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/sj.leu.2404780","volume":"21","author":"DH Kim","year":"2007","unstructured":"Kim DH, Baek JH, Chae YS et al (2007) Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leuk Off J Leuk Soc Am Leuk Res Fund UK 21:2227\u20132230","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"key":"32_CR9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-0609.2008.01129.x","volume":"81","author":"Y Oki","year":"2008","unstructured":"Oki Y, Yamamoto K, Kato H et al (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients\u2019 survival benefit from rituximab. Eur J Haematol 81:448\u2013453","journal-title":"Eur J Haematol"},{"key":"32_CR10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bjh.13332","volume":"169","author":"L Marcheselli","year":"2015","unstructured":"Marcheselli L, Bari A, Anastasia A et al (2015) Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Br J Haematol 169:544\u2013551","journal-title":"Br J Haematol"},{"key":"32_CR11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12185-014-1576-0","volume":"99","author":"S Kumagai","year":"2014","unstructured":"Kumagai S, Tashima M, Fujikawa J et al (2014) Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol 99:737\u2013742","journal-title":"Int J Hematol"},{"key":"32_CR12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","volume":"107","author":"S Camilleri-Bro\u00ebt","year":"2006","unstructured":"Camilleri-Bro\u00ebt S, Crini\u00e8re E, Bro\u00ebt P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190\u2013196","journal-title":"Blood"},{"key":"32_CR13","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/1078-0432.CCR-05-1699","volume":"12","author":"C-H Lin","year":"2006","unstructured":"Lin C-H, Kuo K-T, Chuang S-S et al (2006) Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 12:1152\u20131156","journal-title":"Clin Cancer Res"},{"key":"32_CR14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2010.037408","volume":"96","author":"TM Cardesa-Salzmann","year":"2011","unstructured":"Cardesa-Salzmann TM, Colomo L, Gutierrez G et al (2011) High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 96:996\u20131001","journal-title":"Haematologica"},{"key":"32_CR15","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: r. Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"32_CR16","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116:2040\u20132045","journal-title":"Blood"},{"key":"32_CR17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/neuonc\/not012","volume":"15","author":"M He","year":"2013","unstructured":"He M, Zuo C, Wang J et al (2013) Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma. Neuro Oncol 15:727\u2013734","journal-title":"Neuro Oncol"},{"key":"32_CR18","doi-asserted-by":"crossref","unstructured":"(1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. Int Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 329:987\u2013994","DOI":"10.1056\/NEJM199309303291402"},{"key":"32_CR19","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861","journal-title":"Blood"},{"key":"32_CR20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265","journal-title":"Blood"},{"key":"32_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","volume":"20","author":"J Ruan","year":"2009","unstructured":"Ruan J, Hajjar K, Rafii S, Leonard JP (2009) Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma. Ann Oncol 20:413\u2013424","journal-title":"Ann Oncol"},{"key":"32_CR22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","volume":"4","author":"H Ponta","year":"2003","unstructured":"Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33\u201345","journal-title":"Nat Rev Mol Cell Biol"},{"key":"32_CR23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.humpath.2012.07.007","volume":"44","author":"J Yuan","year":"2013","unstructured":"Yuan J, Gu K, He J, Sharma S (2013) Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression. Hum Pathol 44:606\u2013611","journal-title":"Hum Pathol"},{"key":"32_CR24","first-page":"1063","volume":"9","author":"KM Braaten","year":"2003","unstructured":"Braaten KM, Betensky RA, de Leval L et al (2003) BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9:1063\u20131069","journal-title":"Clin Cancer Res"},{"key":"32_CR25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-8722-7-34","volume":"7","author":"X Wei","year":"2014","unstructured":"Wei X, Xu M, Wei Y et al (2014) The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression. J Hematol Oncol 7:34","journal-title":"J Hematol Oncol"},{"key":"32_CR26","first-page":"1135","volume":"22","author":"M Higashi","year":"2009","unstructured":"Higashi M, Sugaya Y, Soeta S et al (2009) CD44 expression during tumor progression of follicular lymphoma. Oncol Rep 22:1135\u20131140","journal-title":"Oncol Rep"},{"key":"32_CR27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"32_CR28","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","volume":"20","author":"LM DeAngelis","year":"2002","unstructured":"DeAngelis LM, Seiferheld W, Schold SC et al (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93\u201310. J Clin Oncol 20:4643\u20134648","journal-title":"J Clin Oncol"},{"key":"32_CR29","first-page":"1966","volume":"5","author":"P Schraml","year":"1999","unstructured":"Schraml P, Kononen J, Bubendorf L et al (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966\u20131975","journal-title":"Clin Cancer Res"},{"key":"32_CR30","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"C Visco","year":"2012","unstructured":"Visco C, Li Y, Xu-Monette ZY et al (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortiu. Leukemia 26:2103\u20132113","journal-title":"Leukemia"},{"key":"32_CR31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jcp.56.10.747","volume":"56","author":"A Tzankov","year":"2003","unstructured":"Tzankov A, Pehrs A-C, Zimpfer A et al (2003) Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 56:747\u2013752","journal-title":"J Clin Pathol"},{"key":"32_CR32","doi-asserted-by":"crossref","first-page":"e41658","DOI":"10.1371\/journal.pone.0041658","volume":"7","author":"Z-M Li","year":"2012","unstructured":"Li Z-M, Huang J-J, Xia Y et al (2012) Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 7:e41658","journal-title":"PLoS One"},{"key":"32_CR33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clml.2014.10.001","volume":"15","author":"A Belotti","year":"2015","unstructured":"Belotti A, Doni E, Bolis S et al (2015) Peripheral blood lymphocyte\/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Clin Lymphoma Myeloma Leuk 15:208\u2013213","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"32_CR34","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood-2004-03-1209","volume":"104","author":"SL Barrans","year":"2004","unstructured":"Barrans SL, Fenton JAL, Banham A et al (2004) Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104:2933\u20132935","journal-title":"Blood"},{"key":"32_CR35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2008-04-152835","volume":"113","author":"JL Rubenstein","year":"2009","unstructured":"Rubenstein JL, Shen A, Batchelor TT et al (2009) Differential gene expression in central nervous system lymphoma. Blood 113:266\u2013267","journal-title":"Blood"},{"key":"32_CR36","doi-asserted-by":"crossref","unstructured":"Lin B, Chen C, Qian Y, Feng J (2015) Prognostic role of peripheral blood lymphocyte\/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. Leuk Lymphoma 1\u20136","DOI":"10.3109\/10428194.2015.1014367"},{"key":"32_CR37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2007.06596.x","volume":"137","author":"D Behl","year":"2007","unstructured":"Behl D, Ristow K, Markovic SN et al (2007) Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 137:409\u2013415","journal-title":"Br J Haematol"},{"key":"32_CR38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","volume":"134","author":"M Siddiqui","year":"2006","unstructured":"Siddiqui M, Ristow K, Markovic SN et al (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134:596\u2013601","journal-title":"Br J Haematol"},{"key":"32_CR39","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.leukres.2013.07.015","volume":"37","author":"R Watanabe","year":"2013","unstructured":"Watanabe R, Tomita N, Kishimoto K et al (2013) Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res 37:1208\u20131212","journal-title":"Leuk Res"},{"key":"32_CR40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/10428194.2011.637211","volume":"53","author":"RA Wilcox","year":"2012","unstructured":"Wilcox RA, Ristow K, Habermann TM et al (2012) The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 53:575\u2013580","journal-title":"Leuk Lymphoma"},{"key":"32_CR41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27\u201331","journal-title":"Nat Med"},{"key":"32_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000353311","volume":"99","author":"D Ribatti","year":"2014","unstructured":"Ribatti D (2014) History of research on angiogenesis. Chem Immunol Allergy 99:1\u201314","journal-title":"Chem Immunol Allergy"},{"key":"32_CR43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1034\/j.1600-0463.2003.1110406.x","volume":"111","author":"K Norrby","year":"2003","unstructured":"Norrby K, Ridell B (2003) Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and factor VIII. APMIS 111:483\u2013489","journal-title":"APMIS"},{"key":"32_CR44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/10428190601083241","volume":"48","author":"JM J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen JM, S\u00f8rensen FB, Bendix K et al (2007) Angiogenesis in non-Hodgkin\u2019s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 48:584\u2013595","journal-title":"Leuk Lymphoma"},{"key":"32_CR45","first-page":"241","volume":"42","author":"G Mazur","year":"2004","unstructured":"Mazur G, Wr\u00f3bel T, Dziegiel P et al (2004) Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin\u2019s lymphoma. Folia Histochem Cytobiol 42:241\u2013243","journal-title":"Folia Histochem Cytobiol"},{"key":"32_CR46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/BF02782197","volume":"17","author":"O Bairey","year":"2000","unstructured":"Bairey O, Zimra Y, Kaganovsky E et al (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol 17:314\u2013318","journal-title":"Med Oncol"},{"key":"32_CR47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1593\/neo.121962","volume":"15","author":"D Ribatti","year":"2013","unstructured":"Ribatti D, Nico B, Ranieri G et al (2013) The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 15:231\u2013238","journal-title":"Neoplasia"},{"key":"32_CR48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exphem.2009.10.010","volume":"38","author":"S Nagel","year":"2010","unstructured":"Nagel S, Hirschmann P, Dirnhofer S et al (2010) Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol 38:38\u201345","journal-title":"Exp Hematol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-015-0032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-015-0032-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-015-0032-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:39:31Z","timestamp":1559443171000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-015-0032-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s12253-015-0032-7","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"type":"print","value":"1219-4956"},{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}